Fate Therapeutics (FATE) Long-Term Investments (2019 - 2025)

Fate Therapeutics (FATE) has 7 years of Long-Term Investments data on file, last reported at $1.5 million in Q4 2025.

• Quarterly Long-Term Investments fell 94.68% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (down 94.68% YoY) and the FY2025 annual result came in at $1.5 million, down 94.68% from the prior year.
• Long-Term Investments slipped to $1.5 million in Q4 2025, from $10.3 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $149.5 million in Q2 2021 to a low of $980000.0 in Q4 2023.
• A 5-year average of $40.5 million and a median of $26.1 million in 2025 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments slumped 95.09% — and 2024, when it jumped 2722.14%.
• Tracing FATE's Long-Term Investments over 5 years: stood at $100.7 million in 2021, then tumbled by 95.09% to $4.9 million in 2022, then slumped by 80.17% to $980000.0 in 2023, then jumped by 2722.14% to $27.7 million in 2024, then tumbled by 94.68% to $1.5 million in 2025.
• The last three Long-Term Investments figures came in at $1.5 million (Q4 2025), $10.3 million (Q3 2025), and $26.1 million (Q2 2025), per Business Quant data.